Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (1158)	9/24/2001 10:44:01 AM
From: Ian@SI	Respond to of 7143

Stuart, A somewhat longer version of this story appears on the MSNBC health page. It pointed out that the studies were funded by the 2 drug companies with the best patent protection and longest remaining patent life for angiotensin receptor blockers. It further pointed out that other treatments for lowering blood pressure have been proven to be equally effective re kidney disease in Type 1 Diabetics. And it stated that the sponsoring drug companies didn't want the other drugs included in the study as they don't have very good patent protection for those drugs. In short, it appears that a couple drug companies have paid some researchers to help them market their current, most highly priced products regardless of whether or not they're most effective for the condition being treated. FWIW, Ian